OTCMKTS:IPHYF - Innate Pharma Stock Price, News, & Analysis

$7.02
0.00 (0.00 %)
(As of 06/26/2019 03:42 AM ET)
Today's Range
$7.02
Now: $7.02
$7.02
50-Day Range
$6.39
MA: $6.74
$7.25
52-Week Range
$5.07
Now: $7.02
$10.40
VolumeN/A
Average Volume111 shs
Market Capitalization$404.35 million
P/E Ratio117.00
Dividend YieldN/A
Beta0.03
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPHYF
Previous SymbolNASDAQ:IPHYF
CUSIPN/A
CIKN/A
Phone33-04-30-30-30-30

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$110.96 million
Cash Flow$0.2143 per share
Book Value$3.47 per share

Profitability

Miscellaneous

Employees195
Market Cap$404.35 million
Next Earnings Date6/26/2019 (Estimated)
OptionableNot Optionable

Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

When is Innate Pharma's next earnings date?

Innate Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, June 26th 2019. View Earnings Estimates for Innate Pharma.

What price target have analysts set for IPHYF?

1 Wall Street analysts have issued 12-month price targets for Innate Pharma's shares. Their predictions range from $11.00 to $11.00. On average, they expect Innate Pharma's share price to reach $11.00 in the next year. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Innate Pharma.

What is the consensus analysts' recommendation for Innate Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.

Has Innate Pharma been receiving favorable news coverage?

News stories about IPHYF stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a news impact score of 1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the next few days. View News Stories for Innate Pharma.

Who are some of Innate Pharma's key competitors?

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include ADOCIA/S (ADOCY), Cellectis (CLLS), InVitae (NVTA), Allena Pharmaceuticals (ALNA), REDHILL BIOPHAR/S (RDHL), Arbutus Biopharma (ABUS), GTX (GTXI), Obseva (OBSV), Sinovac Biotech (SVA) and ZEALAND PHARMA/S (ZEAL).

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the folowing people:
  • Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
  • Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)
  • Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $7.02.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $404.35 million and generates $110.96 million in revenue each year. The company earns $3.60 million in net income (profit) each year or $0.06 on an earnings per share basis. Innate Pharma employs 195 workers across the globe.View Additional Information About Innate Pharma.

What is Innate Pharma's official website?

The official website for Innate Pharma is http://www.innate-pharma.com/.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]


MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)

Community Ranking:  3.0 out of 5 (star star)
Outperform Votes:  104 (Thanks for Voting!)
Underperform Votes:  72 (Thanks for Voting!)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel